Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B - Windyga, J.; Lissitchkov, T.; Stasyshyn, O.; Mamonov, V.; Rusen, L.; Lamas, J. L.; Oh, M.-S.; Chapman, M.; Fritsch, S.; Pavlova, B. G.; Wong, W.-Y.; Abbuehl, B. E. (Haemophilia : the official journal of the World Federation of Hemophilia, 2014)
Keywords: Adolescent; Adult; Aged; BAX326; Bleeding; Blood Coagulation - drug effects; Child; Factor IX - pharmacokinetics; Factor IX - therapeutic use; Female; haemophilia B; Hemophilia B - blood; Hemophilia B - drug therapy; Humans; Male; Middle Aged; Premedication; previously treated patients; Quality of Life; recombinant factor IX; Recombinant Proteins; Severity of Illness Index; Treatment Outcome; Young Adult; previously treated patients; BAX326; haemophilia B; recombinant factor IX